ArticleCancer biomarkers : section A of Disease markers2021
Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.
Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Research progress of MicroRNA in lung cancer.Discover oncology · 2026Review
- Targeting Oncogenic miRNAs in NSCLC: Therapeutic Strategies and Emerging Approaches.Cancer management and research · 2026Review
- The clinical significance of circulating microRNAs as biomarkers in lung cancer diagnosis and prognosis.Discover oncology · 2025Review
- Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment.Translational lung cancer research · 2025Review
- Functional tumor-derived exosomes in NSCLC progression and clinical implications.Frontiers in pharmacology · 2025Review
- Exosome-Derived miRNAs in Liquid Biopsy for Lung Cancer.Life (Basel, Switzerland) · 2024Review
- Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospects.Journal of pharmaceutical analysis · 2024Review
- A Panorama of Extracellular Vesicle Applications: From Biomarker Detection to Therapeutics.ACS nano · 2024Review
- Characteristics of MicroRNA Expression Depending on the Presence or Absence of Meningioma in Patients with Neurofibromatosis Type 2: A Secondary Analysis.Neurologia medico-chirurgica · 2024Article
- Targeting non-coding RNAs to overcome osimertinib resistance inFrontiers in oncology · 2024Review
- Article
- Composition of Conditioned Media from Radioresistant and Chemoresistant Cancer Cells Reveals miRNA and Other Secretory Factors Implicated in the Development of Resistance.International journal of molecular sciences · 2023Review
- Dysregulated expression of microRNA involved in resistance to osimertinib inJournal of thoracic disease · 2023Article
- Exosomes─Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics.ACS nano · 2022Review
- Extracellular vesicles and particles impact the systemic landscape of cancer.The EMBO journal · 2022Review
- The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer.Journal of personalized medicine · 2022Review
- Molecular Biomarkers in Cancer.Biomolecules · 2022Review
- Extracellular Vesicles and Cell Pathways Involved in Cancer Chemoresistance.Life (Basel, Switzerland) · 2022Review
- Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer.Molecular cancer · 2022Review
- Tumor-derived exosomes: immune properties and clinical application in lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsimertinib is an epidermal growth factor receptor-tyrosine kinase inhibitor that specifically targets the T790M mutation in cancer.Unfortunately, most non-small cell lung cancer (NSCLC) patients develop osimertinib resistance. Currently, the molecular biomarkers for monitoring osimertinib resistance are not available.
objectiveThis study aimed to examine the profile of exosomal miRNA in the plasma of osimertinib-resistant NSCLC patients.
methodsPlasma exosomal miRNA profiles of 8 NSCLC patients were analyzed by next-generation sequencing at osimertinib-sensitive and osimertinib-resistance stage.The expression of dysregulated exosomal miRNAs was validated and confirmed in another cohort of 19 NSCLC patients by qPCR. The relationship between exosomal miRNA upregulation and clinical prognosis, survival analysis was evaluated by Kaplan-Meier curves.
resultsIn osimertinib-resistant NSCLC patients, 10 exosomal miRNAs were significantly dysregulated compared to baseline. Upregulation of all 10 candidate exosomal miRNAs tended to correlate with increased latency to treatment failure and improved overall survival. Among them, 4 exosomal miRNAs, miR-323-3p, miR-1468-3p, miR-5189-5p and miR-6513-5p were essentially upregulated and show the potential to be markers for the discrimination of osimertinib-resistance from osimertinib-sensitive NSCLC patients with high accuracy (p< 0.0001).
conclusionsOur results highlight the potential role of these exosomal miRNAs as molecular biomarkers for the detection of osimertinib resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.